Dr. Hatim Husain, MD

Dr. Husain practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Husain's NPI, 1629234109, was assigned on August 4, 2008. Dr. Husain graduated from Feinberg School of Medicine in 2005. Dr. Husain holds California license A99267.

Dr. Husain's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Husain's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Husain is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Husain to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Husain practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Husain's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Husain is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Husain's licenses on file in 2 states: California and Maryland.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances and lung cancer among the conditions Dr. Husain treats.

CMS data shows 1,928 Medicare services from Dr. Husain across 5 procedure codes in 2024, for 167 Medicare patients. Medicare paid $134,961 for them.

CMS counts 167 Medicare patients who saw Dr. Husain in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have cancer, and 75% have high blood pressure. 37% are also on Medicaid. Their average risk score is 3.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Husain's median patient age at 70, with 59% women.

In 2024, Dr. Husain wrote 662 Medicare Part D claims for 80 patients. 35% of them were for generic drugs. CMS names the drug for 530 of them, across 16 drugs with 11 or more claims each, at $5,596,450 in total drug cost. In 2023, CMS named 544 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Husain for performance year 2024, reported as part of a group. Dr. Husain accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Husain as offering telehealth.

Dmand AI links 35 papers to Dr. Husain, published from 2008 to 2024. 2023 was the busiest year, with 4. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Circulating Tumor DNA. Dr. Husain has published most often in Clin Cancer Res. Dr. Husain's most frequent co-authors are Heather Ann Wakelee, MD, Nam Quoc Bui, MD and Luis Alberto Diaz, MD.

Dmand AI links Dr. Husain to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Lung Neoplasms and Thoracic Neoplasms.

CMS Open Payments shows 2,071 general payments to Dr. Husain from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. AstraZeneca Pharmaceuticals LP paid the most, $740,352. It also lists 15 research payments totaling $42,120 from 2020 to 2024.

Dmand AI lists 1 award for Dr. Husain, most recently CMS Stage 1 EHR in 2013.

Dr. Husain graduated from Feinberg School of Medicine in 2005.

Dr. Husain is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.